Loading...
Loading...
XRTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 43.0K |
| Gross Profit | -43.0K |
| Operating Expense | 1,761.7K |
| Operating I/L | -1,758.2K |
| Other Income/Expense | 240.9K |
| Interest Income | 73.3K |
| Pretax | -1,691.9K |
| Income Tax Expense | -69.8K |
| Net Income/Loss | -1,691.9K |
XORTX Therapeutics Inc. is a bio-pharmaceutical company specializing in the development and commercialization of therapies for progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, and diabetic nephropathy. The company's product portfolio includes XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with COVID-19 and suppress acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy.
